Skip to main content
. 2010 Jul 26;54(10):4440–4445. doi: 10.1128/AAC.01749-09

FIG. 1.

FIG. 1.

Overview of trial design. Volunteers received three treatments in a sequence allocated randomly. Treatments: A, DRV/r 600/100 mg BID on days 1 to 12, with an additional morning dose on day 13; B, RFB 300 mg QD on days 1 to 13; C, DRV/r 600/100 mg BID on days 1 to 13 plus RFB 150 mg QOD from day 1 to 13.